EUVIMEDEUVIMED entdecken
Crossref

Domain-based mRNA vaccines encoding spike protein N-terminal and receptor binding domains confer protection against SARS-CoV-2

Guillaume B E Stewart-Jones iD, Sayda M Elbashir iD, Kai Wu, Diana Lee iD, Isabella Renzi, Baoling Ying iD, Matthew Koch, Caralyn E Sein, Angela Choi iD, Bradley Whitener iD, Dario Garcia-Dominguez iD, Carole Henry und 13 weitere

Science Translational Medicine · 13.09.2023 · 15 (713)

DOI: 10.1126/scitranslmed.adf4100 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Science Translational Medicine, erschienen am 13.09.2023. Verfasst von Guillaume B E Stewart-Jones und 24 weiteren Autor:innen. Beteiligte Einrichtung: Moderna, Inc., Cambridge, MA 02139, USA. Hauptthemen laut MEDLINE: SARS-CoV-2, COVID-19. Die Arbeit wurde bisher 52-mal zitiert (Crossref) und nennt 47 Literaturangaben. Gefördert von: NIAID NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

With the success of messenger RNA (mRNA) vaccines against coronavirus disease 2019, strategies can now focus on improving vaccine potency, breadth, and stability. We designed and evaluated domain-based mRNA vaccines encoding the wild-type spike protein receptor binding domain (RBD) or N-terminal domain (NTD) alone or in combination. An NTD-RBD–linked candidate vaccine, mRNA-1283, showed improved antigen expression, antibody responses, and stability at refrigerated temperatures (2° to 8°C) compared with the clinically available mRNA-1273, which encodes the full-length spike protein. In BALB/c mice administered mRNA-1283 as a primary series, booster, or variant-specific booster, similar or greater immune responses from viral challenge were observed against wild-type, beta, delta, or omicron (BA.1) viruses compared with mRNA-1273–immunized mice, especially at lower vaccine dosages. K18-hACE2 mice immunized with mRNA-1283 or mRNA-1273 as a primary series demonstrated similar degrees of protection from challenge with SARS-CoV-2 Delta and Omicron variants at all vaccine dosages. These results support clinical assessment of mRNA-1283, which has now entered clinical trials (NCT05137236).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

SARS-CoV-2COVID-19AnimalsMice2019-nCoV Vaccine mRNA-1273Spike Glycoprotein, CoronavirusMice, Inbred BALB CRNA, MessengermRNA Vaccines

Substanzen

spike protein, SARS-CoV-22019-nCoV Vaccine mRNA-1273Spike Glycoprotein, CoronavirusRNA, MessengermRNA Vaccines

Autor:innen und Institutionen

  • Moderna, Inc., Cambridge, MA 02139, USA.
  • Department of Medicine, Washington University School of Medicine, Saint Louis, MO 63110, USA.
  • Department of Pathology and Immunology, Washington University School of Medicine, Saint Louis, MO 63110, USA.
  • Department of Molecular Microbiology, Washington University School of Medicine, Saint Louis, MO 63110, USA.

ORCID-Profile: Guillaume B E Stewart-Jones, Sayda M Elbashir, Diana Lee, Baoling Ying, Angela Choi, Bradley Whitener, Dario Garcia-Dominguez, Angela Woods, LingZhi Ma, Chiaowen J Hsiao, Suzanne M Scheaffer, Larissa B Thackray, Phil White, Michael S Diamond

Förderung

  • NIAID NIH HHS

Zitieren

APA

Stewart-Jones, G. B. E., Elbashir, S. M., Wu, K., Lee, D., Renzi, I., Ying, B., Koch, M., Sein, C. E., Choi, A., Whitener, B., Garcia-Dominguez, D., Henry, C., Woods, A., Ma, L., Montes Berrueta, D., Avena, L. E., Quinones, J., Falcone, S., Hsiao, C. J., …, & Carfi, A. (2023). Domain-based mRNA vaccines encoding spike protein N-terminal and receptor binding domains confer protection against SARS-CoV-2. Science Translational Medicine, 15(713). https://doi.org/10.1126/scitranslmed.adf4100

Vancouver

Stewart-Jones GBE, Elbashir SM, Wu K, Lee D, Renzi I, Ying B, et al. Domain-based mRNA vaccines encoding spike protein N-terminal and receptor binding domains confer protection against SARS-CoV-2. Science Translational Medicine. 2023;15(713). doi:10.1126/scitranslmed.adf4100

BibTeX
@article{StewartJones2023,
  author = {Stewart-Jones, Guillaume B E and Elbashir, Sayda M and Wu, Kai and Lee, Diana and Renzi, Isabella and Ying, Baoling and Koch, Matthew and Sein, Caralyn E and Choi, Angela and Whitener, Bradley and Garcia-Dominguez, Dario and Henry, Carole and Woods, Angela and Ma, LingZhi and Montes Berrueta, Daniela and Avena, Laura E and Quinones, Julian and Falcone, Samantha and Hsiao, Chiaowen J and Scheaffer, Suzanne M and Thackray, Larissa B and White, Phil and Diamond, Michael S and Edwards, Darin K and Carfi, Andrea},
  title = {Domain-based mRNA vaccines encoding spike protein N-terminal and receptor binding domains confer protection against SARS-CoV-2},
  journal = {Science Translational Medicine},
  year = {2023},
  volume = {15},
  number = {713},
  doi = {10.1126/scitranslmed.adf4100}
}
Kostenlos starten →